Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | PNK-007: allogeneic NK-cell product post-ASCT in MM

Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, discusses the phase I study (NCT02955550) of single infusion PNK-007, an allogeneic cell therapy product enriched for CD56+/CD3- NK-cells expanded from placental CD34+ cells, after autologous stem cell transplant (ASCT) in multiple myeloma (MM). Prof. Vij reveals PNK-007 with and without recombinant human IL-2 was well tolerated in the post-ASCT setting. Data from this phase I study are encouraging and warrant further evaluation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.